Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BARI | Active Comparator |
| |
| Bio | Active Comparator |
| |
| Tofa | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| "Baricitinib", "olumiant®" | Drug | To examine the effects of baricitinib in RA patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of Disease Activity in rheumatoid patients for 1 year treated by baricitinib (N=30), biologics (N=30), or tofacitinib (N=30). Also, the efficacy and adverse event of each drug for 1 year in the RA patients. | Change from Baseline Values of DAS28-CRP at 1 year in each group |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yukio Nakamura | Recruiting | Matsumoto | Nagano | 3908621 | Japan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000596027 | baricitinib |
| D001688 | Biological Products |
| C479163 | tofacitinib |
| ID | Term |
|---|---|
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| "Biologics" | Drug | To examine the effects of biologics in RA patients |
|
| Tofacitinib 5 MG [Xeljanz] | Drug | To examine the effects of tofacitinib in RA patients |
|
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |